Table 1.
Clinical results and accuracy of non-invasive diagnostic imaging techniques (US, PET-TC, and MRI) in breast cancer assessment of axillary node metastases of studies included in systematic review.
| Trial | Evaluable pts | Diagnostic technique | Sensitivity range | Specificity range | FN rate | Selected characteristics |
|---|---|---|---|---|---|---|
| 722 | US | 64.4–72.7% | 44.1–97.9% | 7–17.5% | Size criterion Both palpable/nonpalpable nodes |
|
| 706 | US | 54.7–92.3% | 80.4–97.1% | 4.2–17.4% | Morphologic criterion Both palpable/nonpalpable nodes |
|
| Alvarez et al., 2006 [8] |
582 | US | 48.8–87.1% | 55.6–97.3% | 5.3–23.1% | Size criterion Nonpalpable nodes |
| 708 | US | 26.4–75.9% | 88.4–98.1% | 8.4–26.9% | Morphologic criterion Nonpalpable nodes |
|
| 822 | US-needle biopsy | 25.9–94.9% | 96.9–100% | 2.3–40.9% | Only needle-biopsied cases | |
| Choi et al., 2012 [9] | 483 | US | 50% | 80.7% | 3.7–15.5% | Pathologic N-stage classification |
| Cooper et al., 2011 [5] |
2591 | PET or PET/TC | 56–66% | 93–96% | 7.2% 0.5% |
Sampling methods replaced with PET PET added to sampling methods |
| Peare et al., 2010 [10] |
2460 | PET | 20–100% | 64–100% | 13.7% | Staging techniques comparison |
| Cooper et al., 2011 [5] |
307 | MRI | 65–98% | 73–100% | 1.9% 0.1% |
Sampling methods replaced with MRI MRI added to sampling methods |
| Lu et al., 2013 [13] |
32 | MRL | 86.2% | 95.3% | 9% | Enhancement defects criteria Lymphatic vessel dilation study |
| Kwak et al., 2013 [14] |
57 |
US/MRI/PET | 82.1% | 45.9% | 1.85–4.03% | Complete preoperative scanning |
MRL: magnetic resonance lymphangiography.